Study of Yersinia pseudotuberculosis surface antigen epitopes using monoclonal antibodies

Byvalov, A. A.; Dudina, L. G.; Litvinets, Sergey G.; Novikova, O. D.; Khomenko, V. A.; Portnyagina, O. Yu.; Ovodov, Yu. S.

doi:10.1134/s0003683814020070

Cited by 7 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to insertions or deletions in 5 of the 17 genes of the O-antigen cluster obtained from Y. pseudotuberculosis O: 1b, Y. pestis produces only the R-form of LPS, consisting of the core and lipid A. The R-form lipopolysaccharide structures in Y. pestis and Y. pseudotuberculosis strains grown at 20–28 °C were demonstrated to be identical and to undergo similar temperature-induced modifications, except for that at 37 °C Y. pestis is unable to incorporate the palmitoyl group and thus produces a lower acylated less immunostimulatory lipid A [ 128 , 129 , 130 ].…”

Section: Omvs-based Vaccines Against Y Pestismentioning

confidence: 99%

“…For a more detailed immunochemical characterization of B antigen, a panel of hybridomas producing monoclonal antibodies (MAbs) raised against Y. pseudotuberculosis surface antigens, including antigen B, was generated. As it turned out, among them were MAbs to the O-side chains of lipopolysaccharide (LPS) [ 129 ], as well as MAbs against different epitopes of membrane proteins of the pathogen [ 126 ]. The first of them reacted with whole bacterial cells, B antigen and LPS preparations.…”

Section: Omvs-based Vaccines Against Y Pestismentioning

confidence: 99%

See 1 more Smart Citation

Yersinia Outer Membrane Vesicles as Potential Vaccine Candidates in Protecting against Plague

et al. 2020

View full text Add to dashboard Cite

Despite the relatively low incidence of plague, its etiological agent, Yersinia pestis, is an exceptional epidemic danger due to the high infectivity and mortality of this infectious disease. Reports on the isolation of drug-resistant Y. pestis strains indicate the advisability of using asymmetric responses, such as phage therapy and vaccine prophylaxis in the fight against this problem. The current relatively effective live plague vaccine is not approved for use in most countries because of its ability to cause heavy local and system reactions and even a generalized infectious process in people with a repressed immune status or metabolic disorders, as well as lethal infection in some species of nonhuman primates. Therefore, developing alternative vaccines is of high priority and importance. However, until now, work on the development of plague vaccines has mainly focused on screening for the potential immunogens. Several investigators have identified the protective potency of bacterial outer membrane vesicles (OMVs) as a promising basis for bacterial vaccine candidates. This review is aimed at presenting these candidates of plague vaccine and the results of their analysis in animal models.

show abstract

Section: Omvs-based Vaccines Against Y Pestismentioning

confidence: 99%

Section: Omvs-based Vaccines Against Y Pestismentioning

confidence: 99%